布隆妥珠單抗
化合物
布隆妥珠單抗（INN：brontictuzumab；開發代號：OMP-52M51）是一種人源化單株抗體，設計用於治療癌症。[1][2]該藥物靶向Notch1並抑制通路激活。[3]
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | Notch 1 |
| 臨床資料 | |
| 其他名稱 | OMP-52M51 |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1447814-75-6 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6392H9862N1980O1710S50 |
| 摩爾質量 | 143,410.36 g·mol−1 |
該藥物由OncoMed開發。
參考資料
編輯- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brontictuzumab, American Medical Association.
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 (PDF). WHO Drug Information. 2014, 28 (2).
- ^ Ferrarotto, R.; Eckhardt, G.; Patnaik, A.; LoRusso, P.; Faoro, L.; Heymach, J. V.; Kapoun, A. M.; Xu, L.; Munster, P. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2018-07-01, 29 (7). ISSN 1569-8041. PMID 29726923. doi:10.1093/annonc/mdy171.